Emerging Markets Earnings: Abbott Laboratories Casts Fortune Abroad
This article was originally published in PharmAsia News
Executive Summary
Emerging markets now account for nearly half of Abbott Laboratories sales – a figure set to grow through regional focus and acquisitions, leading Chicago-based CEO Miles White and other executives to skip over vast portions of the globe in the third quarter earnings call.
You may also be interested in...
Mylan Makes Its Move, Buys Abbott Generics In Tax Inversion Strategy
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.